AstraZeneca PLC (AZN) Puts Heart Warning on Anti-Psychotic Seroquel  
7/20/2011 8:28:56 AM

AstraZeneca is adding a new heart warning to the labels of Seroquel, its blockbuster antipsychotic drug, at the request of the Food and Drug Administration, company and agency officials said on Monday. Warnings for Seroquel will soon recommend that the drug be avoided in combination with 12 drugs linked to arrhythmia. The revised label, posted without fanfare last week on the F.D.A. Web site, says Seroquel and extended-release Seroquel XR “should be avoided” in combination with at least 12 other medicines linked to a heart arrhythmia that can cause sudden cardiac arrest.